William Annett, CEO, OncoCyte discusses the exciting work the company is doing in the liquid biopsy space.  They have developed DetermaVu™ a liquid biopsy test for lung cancer, which studies show has the potential to detect the absence of cancer by analyzing a simple blood sample.  This technique allows individuals to potentially avoid risky, expensive lung biopsies.  The company recently announced promising R&D validation data and is planning to make the test available to patients and physicians later this year. @OncocyteLbx #LiquidBiopsy  #LungCancer #DetermaVu OncoCyte.com